Nuvation Bio Inc. Earnings Per Share, Basic and Diluted
Nuvation Bio Inc. (NUVB) reported Earnings Per Share, Basic and Diluted of -$0.10 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- Nuvation Bio Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.10.
- Nuvation Bio Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.03.
- Nuvation Bio Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.11.
- Nuvation Bio Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.09.
- Nuvation Bio Inc. earnings per share, basic and diluted for fiscal 2021 was -$0.44.
- Nuvation Bio Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.43.
| Period end | Earnings Per Share, Basic and Diluted 2 month | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$0.10 10-Q · filed 2022-05-09 | -$0.12 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$0.44 derived: net income ÷ weighted average shares · filed 2023-11-02 | |
| 2021-12-31 | -$0.03 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$0.12 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$0.25 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$0.44 10-K · filed 2022-02-28 | |
| 2021-09-30 | -$0.11 10-Q · filed 2021-11-10 | -$200.97 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.32 10-Q · filed 2021-11-10 | -$0.77 derived: net income ÷ weighted average shares · filed 2022-11-03 | |
| 2021-06-30 | -$0.09 10-Q · filed 2021-08-12 | -$0.21 10-Q · filed 2021-08-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.66 derived: net income ÷ weighted average shares · filed 2022-11-03 | |
| 2021-03-31 | -$0.12 10-Q · filed 2022-05-09 | -$0.17 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.55 derived: net income ÷ weighted average shares · filed 2022-11-03 | |
| 2020-12-31 | -$0.03 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$0.12 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$0.25 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$0.43 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$0.12 10-Q · filed 2021-11-10 | -$217.52 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$0.32 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 | -$0.10 10-Q · filed 2021-08-12 | -$0.20 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$0.10 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |